<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">37814744</PMID><DateRevised><Year>2023</Year><Month>10</Month><Day>11</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2168-8184</ISSN><JournalIssue CitedMedium="Print"><Volume>15</Volume><Issue>9</Issue><PubDate><Year>2023</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Cureus</Title><ISOAbbreviation>Cureus</ISOAbbreviation></Journal><ArticleTitle>The Burden and Characteristics of Post-COVID-19 Conditions Among Laboratory-Confirmed Delta and Omicron COVID-19 Cases: A Preliminary Study From Maharashtra, India.</ArticleTitle><Pagination><StartPage>e44888</StartPage><MedlinePgn>e44888</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e44888</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.7759/cureus.44888</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Post-COVID-19 conditions (PCC) have emerged as a significant global health concern due to their potential impact on patients' quality of life and healthcare resources. The present study aims to understand the burden and characteristics of PCC in Maharashtra, India, and compares its prevalence among cases infected with Delta and Omicron variants.</AbstractText><AbstractText Label="MATERIAL AND METHODS" NlmCategory="METHODS">A retrospective observational study included 617 laboratory-confirmed Delta and Omicron variant cases. These cases were telephonically followed up to document persistent COVID-19 symptoms using a questionnaire based on the Post-COVID-19 Clinical Form from the Global COVID-19 Clinical Platform of the World Health Organization (WHO), and the results were analyzed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Out of 617 laboratory-confirmed COVID-19 cases, 82.97% and 17.03% were Omicron and Delta cases, respectively. The mean follow-up period for Delta and Omicron cases was 78.05 and 21.56 weeks, respectively. A total of 40 (6.48%) cases reported persistent symptoms at follow-up, with a higher prevalence among those infected with the Delta variant (12.38%) compared to the Omicron variant (5.27%). The most common long COVID symptoms reported were malaise (25%), dyspnea (20%), post-exertional fatigue (17.5%), joint pain (15%), and frequent episodes of cough and cold (15%). Additionally, 1.94% of participants developed a new medical condition following COVID-19 infection, most commonly hypertension (25%), lung fibrosis (16.67%), and asthma (8.33%). Factors&#xa0;such as more than five acute symptoms, a&#xa0;moderate to severe disease, the need for hospitalization, and hospitalization for more than five days were significantly associated with PCC.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Long COVID results in extended disability and illness. The varying impacts of different COVID-19 variants highlight the complex nature of post-COVID-19 complications. Our findings highlight the need for strategic planning of healthcare resources to ensure optimal response and preparedness to manage the burden of PCC.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023, Karyakarte et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Karyakarte</LastName><ForeName>Rajesh P</ForeName><Initials>RP</Initials><AffiliationInfo><Affiliation>Microbiology, Byramjee Jeejeebhoy (BJ) Government Medical College and Sassoon General Hospitals, Pune, IND.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Microbiology, Byramjee Jeejeebhoy Government Medical College (BJGMC), Pune, IND.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Das</LastName><ForeName>Rashmita</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Microbiology, Byramjee Jeejeebhoy (BJ) Government Medical College and Sassoon General Hospitals, Pune, IND.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Microbiology, Byramjee Jeejeebhoy Government Medical College (BJGMC), Pune, IND.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rajmane</LastName><ForeName>Mansi V</ForeName><Initials>MV</Initials><AffiliationInfo><Affiliation>Microbiology, Byramjee Jeejeebhoy (BJ) Government Medical College and Sassoon General Hospitals, Pune, IND.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dudhate</LastName><ForeName>Sonali</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Microbiology, Byramjee Jeejeebhoy (BJ) Government Medical College and Sassoon General Hospitals, Pune, IND.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Agarasen</LastName><ForeName>Jeanne</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Microbiology, Byramjee Jeejeebhoy (BJ) Government Medical College and Sassoon General Hospitals, Pune, IND.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pillai</LastName><ForeName>Praveena</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Microbiology, Byramjee Jeejeebhoy (BJ) Government Medical College and Sassoon General Hospitals, Pune, IND.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chandankhede</LastName><ForeName>Priyanka M</ForeName><Initials>PM</Initials><AffiliationInfo><Affiliation>Microbiology, Byramjee Jeejeebhoy (BJ) Government Medical College and Sassoon General Hospitals, Pune, IND.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Labhshetwar</LastName><ForeName>Rutika S</ForeName><Initials>RS</Initials><AffiliationInfo><Affiliation>Microbiology, Byramjee Jeejeebhoy (BJ) Government Medical College and Sassoon General Hospitals, Pune, IND.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gadiyal</LastName><ForeName>Yogita</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Microbiology, Byramjee Jeejeebhoy (BJ) Government Medical College and Sassoon General Hospitals, Pune, IND.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kulkarni</LastName><ForeName>Preeti P</ForeName><Initials>PP</Initials><AffiliationInfo><Affiliation>Microbiology, Byramjee Jeejeebhoy (BJ) Government Medical College and Sassoon General Hospitals, Pune, IND.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nizarudeen</LastName><ForeName>Safanah</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Microbiology, Byramjee Jeejeebhoy (BJ) Government Medical College and Sassoon General Hospitals, Pune, IND.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mukade</LastName><ForeName>Savita</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Microbiology, Byramjee Jeejeebhoy (BJ) Government Medical College and Sassoon General Hospitals, Pune, IND.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Joshi</LastName><ForeName>Suvarna</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Microbiology, Byramjee Jeejeebhoy (BJ) Government Medical College and Sassoon General Hospitals, Pune, IND.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>09</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cureus</MedlineTA><NlmUniqueID>101596737</NlmUniqueID><ISSNLinking>2168-8184</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">covid-19</Keyword><Keyword MajorTopicYN="N">long covid</Keyword><Keyword MajorTopicYN="N">long haulers</Keyword><Keyword MajorTopicYN="N">post-acute sequelae of sars-cov-2 (pasc)</Keyword><Keyword MajorTopicYN="N">post-covid-19 condition (pcc)</Keyword><Keyword MajorTopicYN="N">sars-cov-2</Keyword></KeywordList><CoiStatement>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>9</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>10</Month><Day>10</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>10</Month><Day>10</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>10</Month><Day>10</Day><Hour>3</Hour><Minute>40</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>9</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37814744</ArticleId><ArticleId IdType="pmc">PMC10560400</ArticleId><ArticleId IdType="doi">10.7759/cureus.44888</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Long covid outcomes at one year after mild SARS-CoV-2 infection: nationwide cohort study. Mizrahi B, Sudry T, Flaks-Manov N, et al. BMJ. 2023;380:0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9832503</ArticleId><ArticleId IdType="pubmed">36631153</ArticleId></ArticleIdList></Reference><Reference><Citation>A clinical case definition of post COVID-19 condition by a Delphi consensus.  [
Jul;
2023 
]. 2021. https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1 https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8691845</ArticleId><ArticleId IdType="pubmed">34951953</ArticleId></ArticleIdList></Reference><Reference><Citation>Post COVID-19 condition (long COVID)  [
Jul;
2023 
]. 2022. https://www.who.int/europe/news-room/fact-sheets/item/post-covid-19-condition  https://www.who.int/europe/news-room/fact-sheets/item/post-covid-19-condition </Citation></Reference><Reference><Citation>Long COVID.  [
Jul;
2021 
]. 2023. https://www.covid.gov/Longcovid/definitions https://www.covid.gov/Longcovid/definitions</Citation></Reference><Reference><Citation>Long COVID or post-COVID conditions.  [
Jul;
2021 
]. 2023. https://www.cdc.gov/coronavirus/2019-ncov/Long-term-effects/index.html https://www.cdc.gov/coronavirus/2019-ncov/Long-term-effects/index.html</Citation></Reference><Reference><Citation>National comprehensive guidelines for management of post-COVID sequelae.  [
Jul;
2021 
]. 2023. https://www.mohfw.gov.in/pdf/NationalComprehensiveGuidelinesforManagementofPostCovidSequelae.pdf https://www.mohfw.gov.in/pdf/NationalComprehensiveGuidelinesforManagementofPostCovidSequelae.pdf</Citation></Reference><Reference><Citation>#IndiaFightsCorona COVID-19.  [
Jul;
2021 
]. 2020. https://www.mygov.in/covid-19/ https://www.mygov.in/covid-19/</Citation></Reference><Reference><Citation>Clinical characteristics of AY.4 infections are similar to B.1.617.2 infections: a preliminary study. Das R, Karyakarte R, Joshi S, et al. Indian J Bas App Med Res. 2021;11:110&#x2013;122.</Citation></Reference><Reference><Citation>An early and preliminary assessment of the clinical severity of the emerging SARS-CoV-2 Omicron variants in Maharashtra, India. Karyakarte RP, Das R, Taji N, et al. Cureus. 2022;14:0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9741711</ArticleId><ArticleId IdType="pubmed">36514661</ArticleId></ArticleIdList></Reference><Reference><Citation>Clinical characteristics and outcomes of laboratory-confirmed SARS-CoV-2 cases infected with Omicron subvariants and the XBB recombinant variant. Karyakarte RP, Das R, Dudhate S, et al. Cureus. 2023;15:0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10035460</ArticleId><ArticleId IdType="pubmed">36968876</ArticleId></ArticleIdList></Reference><Reference><Citation>Global COVID-19 clinical platform case report form (CRF) for post COVID condition (post COVID-19 CRF)  [
Jul;
2023 
]. 2021. https://www.who.int/publications/i/item/global-covid-19-clinical-platform-case-report-form-(crf)-for-post-covid-conditions-(post-covid-19-crf-)  https://www.who.int/publications/i/item/global-covid-19-clinical-platform-case-report-form-(crf)-for-post-covid-conditions-(post-covid-19-crf-) </Citation></Reference><Reference><Citation>Guidelines for COVID-19 vaccination of children between 12-14 years of age.  [
Aug;
2023 
]. 2023. https://vikaspedia.in/health/health-campaigns/all-about-covid-vaccines/guidelines-for-covid19-vaccination-of-children-between-1214-years-of-age https://vikaspedia.in/health/health-campaigns/all-about-covid-vaccines/guidelines-for-covid19-vaccination-of-children-between-1214-years-of-age</Citation></Reference><Reference><Citation>Revised guidelines for home isolation of mild/asymptomatic COVID-19 cases.  [
Aug;
2023 
]. 2021. https://covid19.india.gov.in/document/revised-guidelines-for-home-isolation-of-mild-asymptomatic-covid-19-cases/ https://covid19.india.gov.in/document/revised-guidelines-for-home-isolation-of-mild-asymptomatic-covid-19-cases/</Citation></Reference><Reference><Citation>Government of India, Ministry of Health &amp; Family Welfare: Revised guidelines for home isolation of mild/asymptomatic COVID-19 cases.  [
Aug;
2023 
]. 2022. https://www.mohfw.gov.in/pdf/RevisedHomeIsolationGuidelines05012022.pdf https://www.mohfw.gov.in/pdf/RevisedHomeIsolationGuidelines05012022.pdf</Citation></Reference><Reference><Citation>Statement on the fifteenth meeting of the IHR (2005) Emergency Committee on the COVID-19 pandemic.  [
Jul;
2023 
]. 2023. https://www.who.int/news/item/05-05-2023-statement-on-the-fifteenth-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-coronavirus-disease-(covid-19)-pandemic?gclid=Cj0KCQjwwvilBhCFARIsADvYi7LuVI5QzjCI25N8_P5iC1bwQH3Nr_oAuqHkQys222WrDftu6HKA5xcaAhopEALw_wcB https://www.who.int/news/item/05-05-2023-statement-on-the-fifteenth-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-coronavirus-disease-(covid-19)-pandemic?gclid=Cj0KCQjwwvilBhCFARIsADvYi7LuVI5QzjCI25N8_P5iC1bwQH3Nr_oAuqHkQys222WrDftu6HKA5xcaAhopEALw_wcB</Citation></Reference><Reference><Citation>Long COVID: 3 years in. The Lancet. Lancet. 2023;401:795.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9998094</ArticleId><ArticleId IdType="pubmed">36906338</ArticleId></ArticleIdList></Reference><Reference><Citation>Manifestations and risk factors of post COVID syndrome among COVID-19 patients presented with minimal symptoms - a study from Kerala, India. Anjana NK, Annie TT, Siba S, Meenu MS, Chintha S, Anish TS. J Family Med Prim Care. 2021;10:4023&#x2013;4029.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8797119</ArticleId><ArticleId IdType="pubmed">35136762</ArticleId></ArticleIdList></Reference><Reference><Citation>Post COVID-19 sequelae: a prospective observational study from Northern India. Naik S, Haldar SN, Soneja M, et al. Drug Discov Ther. 2021;15:254&#x2013;260.</Citation><ArticleIdList><ArticleId IdType="pubmed">34719599</ArticleId></ArticleIdList></Reference><Reference><Citation>Characteristics and predictors of long COVID among diagnosed cases of COVID-19. Arjun MC, Singh AK, Pal D, et al. PLoS One. 2022;17:0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9767341</ArticleId><ArticleId IdType="pubmed">36538532</ArticleId></ArticleIdList></Reference><Reference><Citation>Assessment of post COVID-19 health problems and its determinants in North India: a descriptive cross section study. Senjam SS, Balhara YP, Kumar P, et al. medRxiv. 2021:1&#x2013;23.</Citation></Reference><Reference><Citation>Clinical predictors of long COVID-19 and phenotypes of mild COVID-19 at a tertiary care centre in India. Chopra N, Chowdhury M, Singh AK, et al. Drug Discov Ther. 2021;15:156&#x2013;161.</Citation><ArticleIdList><ArticleId IdType="pubmed">34234065</ArticleId></ArticleIdList></Reference><Reference><Citation>Long COVID: major findings, mechanisms and recommendations. Davis HE, McCorkell L, Vogel JM, Topol EJ. Nat Rev Microbiol. 2023;21:133&#x2013;146.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Post-sequelae symptoms and comorbidities after COVID-19. Duggal P, Penson T, Manley HN, et al. J Med Virol. 2022;94:2060&#x2013;2066.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8958980</ArticleId><ArticleId IdType="pubmed">35032030</ArticleId></ArticleIdList></Reference><Reference><Citation>Global prevalence of post-coronavirus disease 2019 (COVID-19) condition or long COVID: a meta-analysis and systematic review. Chen C, Haupert SR, Zimmermann L, Shi X, Fritsche LG, Mukherjee B. J Infect Dis. 2022;226:1593&#x2013;1607.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9047189</ArticleId><ArticleId IdType="pubmed">35429399</ArticleId></ArticleIdList></Reference><Reference><Citation>Prevalence of post-COVID-19 symptoms in hospitalized and non-hospitalized COVID-19 survivors: a systematic review and meta-analysis. Fern&#xe1;ndez-de-Las-Pe&#xf1;as C, Palacios-Ce&#xf1;a D, G&#xf3;mez-Mayordomo V, Florencio LL, Cuadrado ML, Plaza-Manzano G, Navarro-Santana M. Eur J Intern Med. 2021;92:55&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8206636</ArticleId><ArticleId IdType="pubmed">34167876</ArticleId></ArticleIdList></Reference><Reference><Citation>Self-reported long COVID after infection with the Omicron variant in the UK: 18 July 2022.  [
Jul;
2023 
]. 2022. https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/selfreportedLongcovidafterinfectionwiththeomicronvariant/18july2022 https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/selfreportedLongcovidafterinfectionwiththeomicronvariant/18july2022</Citation></Reference><Reference><Citation>Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study. Menni C, Valdes AM, Polidori L, et al. Lancet. 2022;399:1618&#x2013;1624.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8989396</ArticleId><ArticleId IdType="pubmed">35397851</ArticleId></ArticleIdList></Reference><Reference><Citation>Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity. Meng B, Abdullahi A, Ferreira IA, et al. Nature. 2022;603:706&#x2013;714.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8942856</ArticleId><ArticleId IdType="pubmed">35104837</ArticleId></ArticleIdList></Reference><Reference><Citation>Smell and taste disorders in COVID-19: from pathogenesis to clinical features and outcomes. Mastrangelo A, Bonato M, Cinque P. Neurosci Lett. 2021;748:135694.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7883672</ArticleId><ArticleId IdType="pubmed">33600902</ArticleId></ArticleIdList></Reference><Reference><Citation>Long COVID: a review and proposed visualization of the complexity of long COVID. Perumal R, Shunmugam L, Naidoo K, et al. Front Immunol. 2023;14:1117464.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10157068</ArticleId><ArticleId IdType="pubmed">37153597</ArticleId></ArticleIdList></Reference><Reference><Citation>Long Covid or post-acute sequelae of COVID-19 (PASC): an overview of biological factors that may contribute to persistent symptoms. Proal AD, VanElzakker MB. Front Microbiol. 2021;12:698169.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8260991</ArticleId><ArticleId IdType="pubmed">34248921</ArticleId></ArticleIdList></Reference><Reference><Citation>Plasma proteome of long-COVID patients indicates HIF-mediated vasculo-proliferative disease with impact on brain and heart function. Iosef C, Knauer MJ, Nicholson M, et al. J Transl Med. 2023;21:377.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10257382</ArticleId><ArticleId IdType="pubmed">37301958</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>